Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
07 mars 2022 11h14 HE
|
Wave Life Sciences USA, Inc.
Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach Wave’s...
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03 mars 2022 07h30 HE
|
Wave Life Sciences USA, Inc.
Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022 GalNAc-AIMers restore therapeutically relevant levels of AAT for lung...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
24 févr. 2022 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
09 févr. 2022 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
02 févr. 2022 16h05 HE
|
Wave Life Sciences USA, Inc.
Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research Publications highlight the...
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
10 nov. 2021 07h30 HE
|
Wave Life Sciences USA, Inc.
Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly...
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
01 nov. 2021 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences and Takeda Amend CNS Collaboration
18 oct. 2021 17h00 HE
|
Wave Life Sciences USA, Inc.
Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs,...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
29 sept. 2021 08h30 HE
|
Wave Life Sciences USA, Inc.
Trial is expected to enroll 15 boys with DMD amenable to exon 53 skipping First systemically administered therapeutic candidate with PN backbone chemistry modifications to be assessed in the clinic ...